We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals

496 hedge funds and large institutions have $26.7B invested in Alnylam Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 118 funds opening new positions, 170 increasing their positions, 151 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

203% more first-time investments, than exits

New positions opened: 118 | Existing positions closed: 39

83% more funds holding in top 10

Funds holding in top 10: 611 (+5)

62% more capital invested

Capital invested by funds: $16.5B → $26.7B (+$10.2B)

18% more funds holding

Funds holding: 421496 (+75)

17.7% more ownership

Funds ownership: 93.9%111.6% (+18%)

13% more repeat investments, than reductions

Existing positions increased: 170 | Existing positions reduced: 151

11% more call options, than puts

Call options by funds: $298M | Put options by funds: $270M

Holders
496
Holders Change
+75
Holders Change %
+17.81%
% of All Funds
8.54%
Holding in Top 10
11
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+83.33%
% of All Funds
0.19%
New
118
Increased
170
Reduced
151
Closed
39
Calls
$298M
Puts
$270M
Net Calls
+$28.8M
Net Calls Change
-$110M
Name Holding Trade Value Shares
Change
Change in
Stake
Canada Life
126
Canada Life
Manitoba, Canada
$8.51M -$1.41M -7,367 -15%
Susquehanna International Group
127
Susquehanna International Group
Pennsylvania
$8.49M -$4.01M -21,011 -33%
SAM
128
Storebrand Asset Management
Norway
$8.25M -$828K -4,341 -10%
Royal London Asset Management
129
Royal London Asset Management
United Kingdom
$8.13M -$337K -1,769 -4%
RSS
130
Rosenblum Silverman Sutton
California
$8.03M -$472K -2,477 -6%
Robeco Institutional Asset Management
131
Robeco Institutional Asset Management
Netherlands
$7.88M +$7.05M +36,948 +1,532%
SAM
132
Sabadell Asset Management
Spain
$7.88M +$887K +4,650 +13%
Russell Investments Group
133
Russell Investments Group
United Kingdom
$7.87M +$23.8K +125 +0.3%
CII
134
Capital International Inc
California
$7.82M -$591K -3,101 -7%
IBT
135
International Biotechnology Trust
United Kingdom
$7.6M +$6.19M +32,458 +586%
Squarepoint
136
Squarepoint
New York
$7.56M -$16.7M -87,350 -70%
Allspring Global Investments
137
Allspring Global Investments
North Carolina
$7.51M -$306K -1,603 -4%
OCA
138
Octagon Capital Advisors
New York
$7.47M +$7.11M +37,300 New
Mitsubishi UFJ Asset Management
139
Mitsubishi UFJ Asset Management
Japan
$7.45M +$539K +2,825 +8%
HSBC Holdings
140
HSBC Holdings
United Kingdom
$7.18M -$2.76M -14,468 -29%
LOAMS
141
Lombard Odier Asset Management (Switzerland)
Switzerland
$7.13M -$2M -10,491 -23%
Ensign Peak Advisors
142
Ensign Peak Advisors
Utah
$7.11M -$255K -1,335 -4%
DZ Bank
143
DZ Bank
Germany
$7.08M +$6.75M +35,375 New
NC
144
Nekton Capital
United Kingdom
$6.78M +$6.46M +33,890 New
FDCDDQ
145
Federation des caisses Desjardins du Quebec
Quebec, Canada
$6.75M -$154K -806 -2%
SSA
146
Schonfeld Strategic Advisors
New York
$6.73M +$6.41M +33,615 New
ASRS
147
Arizona State Retirement System
Arizona
$6.64M -$72.3K -379 -1%
Brown Advisory
148
Brown Advisory
Maryland
$6.63M -$402K -2,105 -6%
Rafferty Asset Management
149
Rafferty Asset Management
New York
$6.58M +$325K +1,702 +5%
SCM
150
Silverarc Capital Management
Massachusetts
$6.51M +$6.21M +32,545 New

ALNY Hedge Fund Activity: Q3 2022 in Review

496 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2022, worth a combined $26.7B — up 62% from $16.5B a quarter earlier.

Buyers outnumbered sellers: 118 funds opened new ALNY positions and 39 closed out — a net gain of 79 holders — while 170 added to existing stakes and 151 trimmed.

The largest buyer was Nuveen, adding an estimated $3.11B. The largest seller was T. Rowe Price Associates, cutting an estimated $625M.

  • 496 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2022, up from 421 in Q2 2022.
  • Funds reported $26.7B of Alnylam Pharmaceuticals stock for Q3 2022, up 62% quarter-over-quarter.
  • 118 funds opened new Alnylam Pharmaceuticals positions in Q3 2022 and 39 closed out, a net change of +79 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q3 2022 was Nuveen, an estimated $3.11B added.
  • The largest Alnylam Pharmaceuticals seller in Q3 2022 was T. Rowe Price Associates, an estimated $625M sold.

Based on aggregated 13F filings for Q3 2022.